Recombinant Human Carbonic Anhydrase 9 Protein (HEK293)，His

Carbonic Anhydrase 9 (CA9) is a metalloenzyme that plays a crucial role in regulating pH and bicarbonate levels within cells, particularly in hypoxic tumor microenvironments. It catalyzes the reversible hydration of carbon dioxide to bicarbonate and protons, which is vital for various physiological processes, including respiration, acid-base balance, and metabolic function. CA9 is notably overexpressed in several malignancies, including renal cell carcinoma, glioblastoma, and breast cancer, making it a significant biomarker for tumor diagnosis and prognosis. Research has increasingly focused on the development of CA9-targeted therapies and diagnostic tools, as its unique expression pattern in tumors versus normal tissues presents an opportunity for selective cancer treatment. Recombinant proteins of CA9 are utilized for investigating its enzymatic properties, understanding its role in tumor biology, and exploring its potential as a therapeutic target. Advanced techniques in molecular biology and protein engineering have enabled the production of CA9 recombinant proteins for structural studies and drug screening, facilitating the discovery of small molecules that can inhibit its activity. Thus, the study of recombinant CA9 not only enhances our understanding of its biological functions but also propels the development of innovative cancer treatments and diagnostic modalities, pointing towards a promising avenue for future cancer research and precision medicine.